Charles Darwin House, 12 Roger St, London WC1N 2JU Tel: +44 (0)20 7685 2550 [email protected]

Total Page:16

File Type:pdf, Size:1020Kb

Charles Darwin House, 12 Roger St, London WC1N 2JU Tel: +44 (0)20 7685 2550 Info@Rsb.Org.Uk The Royal Society of Biology Register of Eligible Qualified Persons – Web Version Copyright © 2013 The Royal Society of Biology All rights reserved No part of this register may be reproduced, copied or transmitted in any form or by any means without written permission from the Royal Society of Biology Anyone wishing to use details from the Register must contact the Professional Registers Programme Manager BAKER, C CBiol MRSB QualiPharm Consultancy Ltd Tel: 07968 266691 Email: [email protected] Website: www.qualipharm.co.uk Registered 2007 BARNARD DD, CBiol Holly Lodge LLantilio Crossenny Monmouthshire NP7 8TF Registered 1992 BERLANGA H, CBiol MRSB Allergy Therapeutics plc Dominion Way | Worthing West Sussex BN14 8SA Tel: 01903 844 703 Email: [email protected] Website: www.allergytherapeutics.com Registered 2011 BIRCH I, CBiol MRSB BECO Integrated Services Ltd Email: [email protected] Charles Darwin House, 12 Roger St, London WC1N 2JU Tel: +44 (0)20 7685 2550 [email protected] www.rsb.org.uk Registered Charity No.277981 Incorporated by Royal Charter Registered 2010 BURROWS M, MRSB Shire Pharmaceuticals Ireland Ltd Miesian Plaza 50 -58 Lower Baggot Street Dublin DO2 Y754 Tel: 0877112159 Email: [email protected] Registered 2015 CALLAGHAN M, MRSB Piramal Pharma Solutions Email: [email protected] CHESTERTON NJ, MRSB Dolby Vivisol Unit 18 Arkwright Road Bedford Bedfordshire MK42 0LQ Tel: 07584 086330 Email: [email protected] Registered 2011 CLACK S, CBiol MRSB Quaph Consulting Ltd Email: [email protected] Website: www.quaph.co.uk Registered 2005 CLARK N, MRSB Eurocaps Ltd Crown Business Park Dukestown Tredegar Blaenau Gwent NP22 4EF Tel: 01495 308900 Email: [email protected] Website: www.eurocaps.co.uk Registered 2016 2 CONNOR N A, CBiol MRSB NC (QP Services) Limited Registered 2002 DALTON L, MRSB Medimmune Ltd (AstraZeneca) Aaron Klug Building Granta Park Cambridge CB21 6GH Tel: 020 374 961 56 Email: [email protected] DAVIES-HODGKINSON N, CBiol MRSB AstraZeneca Derwent Building Silk Road Business Park Charrterway Macclesfield Cheshire SK10 2NA Tel: 01625 519545 Email: [email protected] Registered 1994 DIXON FM, CBiol Astrazeneca GES, Operations Quality AH4H 400-8 Alderley House Alderley Park Macclesfield Cheshire SK10 4TG Tel: 01625 516598 Email: [email protected] DOUGLAS M, Norgine New Road, Tir-y - berth, Hengoed Mid Glamorgan CF82 8SJ Tel: 01443 812183 Mob: 0752 173 1696 Email: [email protected] Registered 2009 3 EVEREST Y, CBiol GSK Priory Street Ware Hertfordshire SQ12 0DJ Registered 2005 FARRER D, CBiol MRSB Pharma Alliance International Email: [email protected] Website: www.pharma-alliance.com Registered 2000 HARBINSON T, CBiol Pfizer Ltd Sandwich Kent CT13 9NJ Tel: 01304 644109 Email: [email protected] Registered 2011 HART F, MRSB GlaxoSmithKline Building H89 New Frontiers Science Park Harlow, Essex CM19 5AW Tel:07966786015 Email|: [email protected] Registered 1998 HAZELL AT, CBiol MRSB 71 Prestwick Drive Bishops Stortford Hertfordshgire CM23 5ER Tel: 01279 507039 Email: [email protected] Registered 2002 HUNT CC, CBiol MRSB 11 Halifax Way Weleyn Garden city Herts AL7 2QH 4 Tel: 079764667 Email: [email protected] JONES D, CBiol MRSB Pharmasssure International Limited 8 Whitefield Road Sale M33 8NZ Tel: 07503 207 207 Email: [email protected] Registered 2005 JONES GT, CBiol MRSB Bristol-Myers Squib Reeds Lane Moreton Wirral Merseyside CH46 1QW Tel: 0151 552 1726 Email:[email protected] Registered 1992 JONES SL, CBiol MRSB SJ Consultancy Services 64 Andrews Way Hatt, Saltash Cornwall PL12 6PE Email: [email protected] Registered 2001 KEY C, CBiol MRSB Registered 1990 JONES T L, CBiol MRSB AbbVie Sovereign House 1-2 Bingham Road Sittingbourne Kent ME10 3SU Tel: +44 7795 305529 Email: [email protected] 5 LANCASTER MJ, MRSB Mark Lancaster Quality Services Limited 47 Stoke Farthing Salisbury Wiltshire SP5 5ED Tel: 07935251130 Email: [email protected] Registered 2001 MAYHALL T, CBiol MRSB MQA Solutions York Email: [email protected] Website: www.mqasolutions.co.uk Registered 1994 McCoy Vickers L, CBiol MRSB 21 Chevington road Chedburgh Bury St Edmunds Suffolk IP29 4UL Tel: 07411218588 Email: [email protected] Registered 2006 McGregor JSL, CBiol MRSB 3M Healthcare Registered MOORE P, MRSB 6 Mount Pleasant Avenue Newtownabbey Antrim BT37 0NE Email: [email protected] Registered 1992 O’CONNELL R, CBiol MRSB Registered 2008 6 OGUNSANLU A, CBiol Pharmacy Department Imperial College Healthcare NHS Trust Charing Cross Hospital Fulham Palace Road London W6 8RF Tel: 020 3311 1706 Email: [email protected] Registered 2011 O’HAGAN K, CBiol TecMac UK Ltd 16 Melvinshaw Leatherhead Surrey KT22 8SX Tel: 07957 552430 Email: [email protected] Registered 2003 PALLISTER S M, CBiol MRSB Tel: 07768391333 Email: [email protected] Registered 2000 PALMER PR, CBiol MRSB Paul R Palmer Ltd Amelia House Crescent Road Worthing West Sussex BN11 1QR Tel: 01903366167 Email: [email protected] Website: www.qp.solutions PARK SP, CBiol, MRSB Pharmaccord Products Ltd 4 Betjeman Road Marlborough SN8 1TL Tel: 01672 514741 Email: [email protected] Registered 1993 7 PARSONS DG, CBiol MRSB GSK Consumer Healthcare St George’s Avenue Weybridge, Surrey KT13 0DE Tel: 01932 822000 Email: [email protected] Registered 1995 PULLEN, N, CBiol MRSB Celgene Europe Ltd Email: [email protected] Registered 2003 RAW N, CBiol MRSB Raw Quality Consultants 23 Forest Close Baughurst Tadley Hampshire RG26 5PB Email: [email protected] RYAN MG, CBiol MRSB Oxford BioMedica (UK) Ltd The Medawar Centre Robert Robinson Avenue The Oxford Science Park Oxford – OX4 4GA Tel: 01865 783000 Email: [email protected] Registered 2011 SALAHUDEEN MA, MRSB Bio Products Laboratories Dagger Lane Elstree Herts WD6 3BX Tel: 07764280275 Email: [email protected] Registered 2012 8 SANDERS B, CBiol MRSB Nottingham University Hospitals NHS Trust QC Unit F Floor West Block Queens Medical Centre Derby Road Nottingham NG7 2UH Tel: 01159709432 Email: [email protected] Registered 1995 SHEPPERSON N, CBiol FRSB 184 Rake End Hill Ridware Rugeley, Staffs WS15 3RQ Email: [email protected] Registered 2005 SIMS C, CBiol, MRSB Registered 2003 SKELTON SC, CBiol MRSB Registered 1985 SMITH B, MRSB GSK Harlow, Essex Email: [email protected] Registered 2011 TEMPLE R, AMRSB Glaxo SmithKline Priory Street Ware , Herts SG12 0DJ Tel: 01920 862537 Email: [email protected] Registered 2009 9 URWIN, C CBiol MRSB MSD Cramlington Northumberland Registered 2007 VICKERY H, MRSB Baxter Healthcare Caxton Way Thetford Norfolk Tel: 01842 767074 Email: [email protected] Registered 2012 WAYMAN N, CBiol MRSB Congleton Cheshire Registered 2002 WEATHERHEAD M-A, CBiol, MRSB Pfizer 32 New Lane, HAVANT, PO9 2NG Tel: 02392 682125 Email: [email protected] Registered 2010 WEINZWEIG JM, CBiol, FRSB Home Farm Coytrehen Bridgend CF32 8YS Company: Weinzweig Enterprises but on Biotec International Services Ltd licence Tel: 07943811128 Email: [email protected] Registered 2009 YEARDLEY G, CBiol MRSB Yeardley QP Services Black Bull Cottage West Road Melsonby Richmond North Yorkshire DL10 5ND 10 Tel: 01325718488 Email: [email protected] Registered 1998 11 .
Recommended publications
  • Alderley Park the Future As a World-Class Life Science Facility Planning Application Summary Document
    DECEMBER 2015 ALDERLEY PARK THE FUTURE AS A WORLD-CLASS LIFE SCIENCE FACILITY PLANNING APPLICATION SUMMARY DOCUMENT Alderley Park is a world-class Life Science research and development (R&D) facility. The site currently houses around 190,000 sq m of premier scientific laboratory space, offices, restaurants, cafes, conferencing space and energy plant, set in 400 acres of parkland. As a centre for scientific research, it is one of the few facilities in the country with a comprehensive offering to support drug discovery and development. It was AstraZeneca’s global lead centre for cancer research, employing at its peak up to 10,000 people in highly skilled jobs. These facilities at Alderley Park are high-quality A planning application has been submitted to and high-tech, and require significant ongoing Cheshire East Council for future development investment to retain them. £550 million has been at Alderley Park. The planning application invested in Alderley Park since 1997 and further, has been allocated the reference number major investment is required to repurpose the site 15/5401M. from single to multi-occupier use, maintain the facilities and cover ongoing overheads. This summary document sets out the key elements of the proposals. ILLUSTRATIVE MASTERPLAN SIGNIFICANT INVESTMENT PROPOSED OVER THE NEXT 10 YEARS In March 2013, AstraZeneca announced The site was purchased by Bruntwood/MSP, its decision to relocate its R&D facilities to part of Alderley Park Ltd who now wish to Cambridge, leading to uncertainty over the secure the future of the site, retaining talent and future of Alderley Park and its role in the local jobs, by taking forward the Taskforce’s vision.
    [Show full text]
  • Novel Neutralizing Hedgehog Antibody MEDI-5304 Exhibits Antitumor Activity by Inhibiting
    Author Manuscript Published OnlineFirst on December 16, 2013; DOI: 10.1158/1535-7163.MCT-13-0420 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Fully Human Anti-Hedgehog Antibodies Novel neutralizing hedgehog antibody MEDI-5304 exhibits antitumor activity by inhibiting paracrine hedgehog signaling. Authors: Neil R. Michaud1*, Youzhen Wang1, Kristen McEachern1, Jerold J. Jordan1, Anne Marie Mazzola1, Axel Hernandez1, Sanjoo Jalla2, Jon W. Chesebrough2, Mark J. Hynes3, Matthew Belmonte 1, Lidong Wang3, Jaspal S. Kang4#, Jelena Jovanović5, Naomi Laing1, David W. Jenkins1, Elaine Hurt2, Meina Liang6, Christopher Frantz7, Robert E. Hollingsworth2, Diane M. Simeone3, David C. Blakey8, and Vahe Bedian1* Authors’ affiliation: 1Oncology iMED, AstraZeneca-R&D Boston, Waltham, MA 2Oncology Research, MedImmune LLC, Gaithersburg, MD 3Translational Oncology Program, University of Michigan, Ann Arbor, MI; 4Amgen British Columbia, Burnaby, BC, Canada 5Lead Generation- Research, Medimmune LLC, Granta Park, Cambridge, UK 6Clinical Pharmacology and DMPK, MedImmune LLC, Hayward, CA 7Biologics Safety Assessment, MedImmune LLC, Mountain View, CA 8Oncology iMed, AstraZeneca, Alderley Park, Macclesfield. UK #Current address: Paul Kang, CSO, Innovative Targeting Solutions Inc., Burnaby BC, Canada *corresponding authors: Neil R. Michaud, Ph.D. Oncology iMED AstraZeneca-R&D Boston Waltham, MA 02451 e-mail: [email protected] Vahe Bedian Ph.D. Oncology iMED AstraZeneca-R&D Boston Waltham, MA 02451 phone:781-839-4613 e-mail: [email protected] Running title: Fully Human Anti-Hedgehog Antibodies Key Words: Hedgehog, Antibody, Xenograft, XenoMouse, cancer stem cells Grant Support: This work was funded by AstraZeneca PLC and MedImmune LLC. Disclosure of Potential Conflicts of Interest: There are no potential conflicts of interest.
    [Show full text]
  • 6Th Annual Translational Medicine Conference City Hotel, Derry/Londonderry, Northern Ireland 25Th - 26Th Sept 2014
    6th Annual Translational Medicine Conference ‘Personalising Health and Care’ Date: 25th and 26th September 2014 | Venue: City Hotel, Derry/Londonderry, N.Ireland, UK 1 6th Annual Translational Medicine Conference City Hotel, Derry/Londonderry, Northern Ireland 25th - 26th Sept 2014 Conference Sponsors 2 6th Annual Translational Medicine Conference City Hotel, Derry/Londonderry, Northern Ireland 25th - 26th Sept 2014 Contents Page Conference Programme .................................................................................... 4 Biographies .......................................................................................................... 6 - 9 Delegate List ........................................................................................................ 10 - 12 Bio-Entrepreneur Programme........................................................................ 13 About C-TRIC ....................................................................................................... 14 - 15 Abstracts Poster Presentations................................................................. 16 - 42 Abstracts Oral Presentations................................................................. 43 Abstracts Poster List................................................................. 44 3 6th Annual Translational Medicine Conference City Hotel, Derry/Londonderry, Northern Ireland 25th - 26th Sept 2014 ‘Personalising Health and Care’ - Conference Programme Day One Thursday 25th Sept 1:00 pm Registration and Tea/Coffee 4.30 pm Oral
    [Show full text]
  • Alderley Park Development Framework
    Alderley Park Development Framework Consultation Draft - January 2015 0i 2 Contents 1 Introduction 2 The Site 3 Planning Policy 4 Design Guidance 5 Indicative Masterplan 6 Planning Applications 7 Summary and Next Steps Appendices 3 1 Introduction Alderley Park, a research and development site The Taskforce commissioned a study to establish the new vision for the site. It allocates Alderley Park as an renowned for the discovery and development of potential future demand from the life science sector, for ‘opportunity site’, seeking to promote and encourage the innovative new medicines, is a key part of the North the world class laboratory and office space on site1. That development of the Life Science Park whilst recognising West Life Science Ecosystem. Opening more than 40 study indicated that whilst there would not by any means that there is likely to be a need for a degree of flexibility years ago, the site has a rich heritage of important be an instant demand for all the site’s facilities, with an regarding land uses to deliver, grow and sustain the Life advancements in medical treatments, including a appropriate business model, there is potential to build on Science Park vision. number of anti-cancer treatments. As the lead centre the BioHub concept, repurposing the site to offer facilities Until the adoption of the CELPS, the current development for cancer research, Alderley Park currently houses which complement existing life science resources across plan for the area remains the Macclesfield Borough the global Advanced Lead Discovery Centre, and its the region, such that Alderley Park can continue to be a Local Plan.
    [Show full text]
  • Directions to Alderley Park Conference Centre
    Directions to Alderley Park Conference Centre Travel by rail Travel by road Travel by air A regular shuttle service from Alderley Alderley Park is centrally located on Alderley Park is located within 20 minutes Park provides convenient transfer from both the UK’s North/South and East/ drive time on uncongested roads to nearby Wilmslow and Macclesfield mainline West motorway network. The main M6 Manchester Airport, which serves more stations, connecting with direct services motorway is just 20 minutes’ drive away destinations than any other airport in to London that run every 20 minutes and on uncongested roads. Manchester city the UK. This top 20 international airport take under two hours. Manchester is a key centre can be accessed in 40 minutes and handles over 22m passengers every year rail hub on the West Coast mainline linking Liverpool and Leeds can be reached within to over 220 worldwide destinations allowing London with Scotland as well as being the one hours’ drive time, with Birmingham comprehensive direct flight access to main arterial rail link between England, two hours drive time from site. On-site car Europe, the US and the Far East. In addition Wales and Scotland. parks at Alderley Park can accommodate Liverpool airport is 40 miles away and approximately 4,000 vehicles. Birmingham West Midlands is 71 miles away. Regional map Local map TO MANCHESTER AIRPORT M6 to Preston, M62 to Leeds MANCHESTER Carlisle, Scotland ROAD 4 3 A34 - TO M66 A M6 Rochdale M60 J3 & MANCHESTER Heywood Bury M62 W A T E R L A Bolton N E 8 WILMSLOW
    [Show full text]
  • Large-Scale Isolation of Human Skeletal Muscle Satellite Cells from Post-Mortem Tissue and Development of Quantitative Assays to Evaluate Modulators of Myogenesis
    J Cachexia Sarcopenia Muscle (2013) 4:157–169 DOI 10.1007/s13539-012-0097-z ORIGINAL ARTICLE Large-scale isolation of human skeletal muscle satellite cells from post-mortem tissue and development of quantitative assays to evaluate modulators of myogenesis Ian C. Scott & Wendy Tomlinson & Andrew Walding & Beverley Isherwood & Iain G. Dougall Received: 24 July 2012 /Accepted: 25 November 2012 /Published online: 24 January 2013 # Springer-Verlag Berlin Heidelberg 2013 Abstract Methods Satellite cells were isolated by digestion of post- Background During aging, there is a decreased ability to mortem skeletal muscle and selection using anti-CD56 maintain skeletal muscle mass and function (sarcopenia). MicroBeads. CD56+ cell-derived myotubes were quantified Such changes in skeletal muscle are also co-morbidities by high content imaging of myosin heavy chains. TaqMan- of diseases including cancer, congestive heart failure polymerase chain reaction arrays were used to quantify expres- and chronic obstructive pulmonary disease. The loss of sion of 41 selected genes during differentiation. The muscle mass results in decreased strength and exercise effects of activin receptor agonists and tumour necrosis tolerance and reduced ability to perform daily activities. factor alpha (TNFα) on myogenesis and gene expres- Pharmacological agents addressing these pathologies sion were characterised. could have significant clinical impact, but their identifi- Results Large-scale isolation of CD56+ cells enabled devel- cation requires understanding of mechanisms driving opment of a quantitative myogenesis assay with maximal myotube formation (myogenesis) and atrophy and pro- myotube formation 3 days after initiating differentiation. vision of relevant assays. The aim of this study was to Gene expression analysis demonstrated expression of 19 develop robust in vitro methods to study human genes changed substantially during myogenesis.
    [Show full text]
  • Cardiovascular Safety Risk Assessment for New Candidate Drugs from Functional and Pathological Data
    Cardiovascular safety risk assessment for new candidate drugs from functional and pathological data 14th & 15th November 2013 Alderley Park Conference Centre, Cheshire, UK The 28th annual meeting of the British Society of Toxicological Pathology (BSTP) held jointly with the Safety Pharmacology Society (SPS) Cardiovascular safety risk assessment for new candidate drugs from functional and pathological data th th 14 & 15 November 2013, Alderley Park Conference Centre, UK 28th ANNUAL SCIENTIFIC MEETING of the BRITISH SOCIETY OF TOXICOLOGICAL PATHOLOGY held jointly with the SAFETY PHARMACOLOGY SOCIETY I am delighted to welcome you to the 28th annual meeting of the British Society of Toxicological Pathology (BSTP) held jointly with the Safety Pharmacology Society (SPS) and sponsored by the Health and Environmental Sciences Institute (HESI) at The Alderley Park Conference Centre, Cheshire, UK on 14th and 15th November 2013. The excellent programme on offer at this meeting is a tribute to the work of many people, including the BSTP Council and Education Sub-Committee. However, I would particularly like to thank the Scientific Organisers, Stephanie Klein and Will Redfern, for their ideas and energy in successfully combining morphologic and functional aspects of cardiovascular toxicology. This was the aspiration of the meeting and I think it has been fulfilled. We know that much scientific progress is made at the intersection of different disciplines, and the BSTP is keen to establish fruitful collaborations with many other societies. This results in meetings of wider interest and allows for hot topics at the edge of our current understanding to be discussed. This meeting, organised with Jean-Pierre Valentin of the SPS, very much exemplifies this approach and I hope it forms the template of many more to come.
    [Show full text]
  • Impact of the Disinvestment by Astrazeneca at Alderley Park, Cheshire Volume 1: Economic Impact Assessment Final Report
    Impact of the disinvestment by AstraZeneca at Alderley Park, Cheshire Volume 1: Economic Impact Assessment Final Report Commercial in Confidence 29 January 2014 Impact of the disinvestment by AstraZeneca at Alderley Park, Cheshire Volume 1: Economic Impact Assessment Contents Executive Summary .................................................................................................................. i 1. Introduction .......................................................................................................................... 1 2. Setting the Scene ................................................................................................................. 4 3. Research Method & Impact Parameters .......................................................................... 13 4. The Quantitative Contribution of AstraZeneca at Alderley Park – ‘pre-disinvestment ’ ................................................................................................................................................. 22 5. The Quantitative Contribution of AstraZeneca at Alderley Park – ‘post-disinvestment ’ ................................................................................................................................................. 33 6. The Wider Qualitative effects of disinvestment .............................................................. 37 7. Perspectives on the Spatial Effects and Consequences of Disinvestment ................. 43 8. Conclusions & Recommendations ..................................................................................
    [Show full text]
  • The Impact of the Disinvestment by Astrazeneca at Alderley Park, Cheshire Final Report Contents
    The i mpact of the disinvestment by AstraZeneca at Alderley Park, Cheshire Volume 2: Future Market Demand Assessment Final Report Commercial in Confidence 11 February 2014 The impact of the disinvestment by AstraZeneca at Alderley Park, Cheshire Final Report Contents Executive Summary .................................................................................................................. i 1. Introduction .......................................................................................................................... 1 2. Setting the Scene ................................................................................................................. 5 3. Thinking & Planning for Demand ..................................................................................... 30 4. Projection 1 – An Initial Perspective on Demand ........................................................... 43 5. Qualitative Perspectives on Demand – the General View ............................................. 53 6. Qualitative Perspectives on Demand – the particular case of HE and Research Institutes ................................................................................................................................. 72 7. Projection 2 - A Revised Perspective on Demand .......................................................... 78 8. The Story of Existing and Pipeline Supply ...................................................................... 81 9. A Forward View of Economic Impact ..............................................................................
    [Show full text]
  • 022405Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 022405Orig1s000 PHARMACOLOGY REVIEW(S) MEMORANDUM Vandetanib Date: March 25, 2011 To: File for NDA 22405 From: John K. Leighton, PhD, DABT Associate Director for Pharmacology/Toxicology Office of Oncology Drug Products I have examined pharmacology/toxicology supporting review and labeling provided by Drs. Gehrke and Dorsam and supervisory memorandum provided by Dr. Verbois. I concur with their conclusions that vandetanib may be approved for the proposed indication with the carcinogenicity studies to be provided as described in the Action Letter. Reference ID: 2923639 --------------------------------------------------------------------------------------------------------- This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature. --------------------------------------------------------------------------------------------------------- /s/ ---------------------------------------------------- JOHN K LEIGHTON 03/25/2011 Reference ID: 2923639 MEMORANDUM Date: March 25, 2011 From: S. Leigh Verbois, Ph.D. Supervisory Pharmacologist Division of Drug Oncology Products To: File for NDA #022405 Vandetinib Re: Approvability of Pharmacology and Toxicology Non-clinical studies that investigated the pharmacology and toxicology of vandetinib provided to support NDA 022405 for the treatment of patients with unresectable locally advanced or metastatic medullary thyroid cancer were reviewed in detail by Brenda Gehrke,
    [Show full text]
  • Site Selection Final Report: Alderley Park
    Cheshire East Local Plan Site Selection Final Report: Alderley Park July 2016 Contents 1 Introduction 1 2 Sustainability Appraisal 2 3 Neighbourhood Plan 2 4 Sites Assessed and Recommendation 2 Site PSS1200 2 5 Overall Conclusion (Stage 9) 6 Appendices Appendix 1: Site Map 7 Appendix 2: Traffic Light Form 9 Appendix 3: Vision and Strategic Priorities Form 16 Appendix 4: Summary of Infrastructure Providers and Statutory Consultee Comments 20 Cheshire East Local Plan Strategy: Final Site Selection Report Alderley Park 1. Introduction 1.1 The ‘Cheshire East Local Plan Strategy: Site Selection Report – Alderley Park was published as background evidence to the Cheshire East Local Plan Strategy Proposed Changes Version (LPS) consultation, which took place from 4 March to 19 April 2016. The Report documented the implementation of the Site Selection Methodology (SSM) for Alderley Park. 1.2 This Report considers: (i) any additional information that has been submitted, in relation to the site and whether such information means that the conclusion and recommendation, using the SSM should change, in relation to the site; (ii) the responses, relating to the site, submitted to the public consultation in March/April 2016. 1.3 This Report supersedes the March 2016 Report; it makes it clear where circumstances have changed in relation to the site and makes recommendations accordingly, some of which may be different to those made in the March 2016 Report. 1.4 This Report should be read alongside the SSM report (and its associated evidential documents, including the Urban Potential Assessment (UPA) [PS E039b], and Edge of Settlement Assessment (ESA) [PS E039b]), the Sustainability Appraisal (SA)/Habitats Regulations Assessment (HRA), and the Cheshire East Council Proposed Changes to the Local Plan Strategy (Consultation Draft) February 2016.
    [Show full text]
  • Organization Name Add1 Add2 Add3 City A. Menarini Diagnostics Ltd Wharfedale Road Winnersh Wokingham Berkshire A1 Pharmaceutical
    Organization Name Add1 Add2 Add3 City A. Menarini Diagnostics Ltd Wharfedale Road Winnersh Wokingham Berkshire A1 Pharmaceuticals Plc Units 3/4 Bessemer Park Ind.Est 250 Milkwood Road Herne Hill London AAF Bassington Lane Cramlington Northumbeland AAH Medical Unit 20 - Broombank Business Park Broombank Rd. Sheepbridge Chesterfield Derbyshire AAH Pharmaceuticals Ltd Walsgrave Triangle Walsgrave Coventry West Midlands Abbott Laboratories Limited Abbott House Norden Road Maidenhead Berks Aber Instruments Ltd Science Park Aberystwyth Aberystwyth Abertec Ltd The Old College Kings Street Aberystwyth Aberystwyth abtec Biologicals Ltd 396 Scotland Road Taylor Street I E Liverpool Merseyside Acambis PLC Peterhouse Technology Park 100 Fulbourn Road Cambridge Cambridgeshire Actinova Ltd 5 Signet Court Swanns Road Cambridge Cambs Adams Healthcare Ltd Lotherton Way Garforth Leeds Adaptive Biosystems Ltd 15 Ribocon Way Progress Business Park Luton Beds Adelphi (Tubes) Ltd Millgreen Road Haywards Heath West Sussex Advanced Biotechnologies Ltd Unit Units B1 & B2 Longmead Business Centre Blenheim Road Surrey Epsom Advanced Medical Solutions Group Plc Road Three Winsford Industrial Estate Windsford Cheshire Advanced Technologies (Cambridge) Ltd (ATC) 210 Cambridge Science Park Milton Road Cambridge Cambs Advante Holdings (UK) Ltd Plant Breeding Station Boothby Graffoe Lincs Aea Technology Biotechnology Services 353 Harwell Didcot Oxfordshire AEA Technology plc AEA Technology Biosciences F4 Culham Science Centre Abingdon Oxon AERES Biomedical Ltd 1-3 Burtonhole
    [Show full text]